From: Investigator experiences with financial conflicts of interest in clinical trials
Practice | Rationale |
---|---|
Signed contracts reviewed by institution [18] | Reduce the risk of transparency bias |
Signed contracts do not have restrictive confidentiality clauses that prevent disclosure of trial information without permission from the funder [17, 18, 29] | Reduce the risk of publication bias |
Budgetary reviewed by a REB or institutional official [3] | Reduce the risk of transparency bias |
Registration of a trial in a WHO approved registry since the requirement for trial registration in 2005 [10, 30, 31] | Reduce the risk of publication bias [32] |
Investigators rather than funder should have data ownership [17, 18, 33] | Reduce the risk of reporting bias |
Investigator should have access to data from all sites [11, 12] | Reduce the risk of reporting bias |
Funder should not control final decisions regarding | Â |
Reduce the risk of biased study designs | |
Reduce the risk of biased analyses | |
Reduce the risk of biased interpretation | |
Funder should not control final decision on content of submitted manuscripts [11, 12] | Reduce the risk of reporting bias |
There should be no ghost authorship [34] | Reduce the risk of reporting bias |